These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 36670542)
1. Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas. Varadi M; Nagy N; Reis H; Hadaschik B; Niedworok C; Modos O; Szendroi A; Ablat J; Black PC; Keresztes D; Csizmarik A; Olah C; Gaisa NT; Kiss A; Timar J; Toth E; Csernak E; Gerstner A; Mittal V; Karkampouna S; Kruithof de Julio M; Gyorffy B; Bedics G; Rink M; Fisch M; Nyirady P; Szarvas T Cancer Med; 2023 Apr; 12(7):9041-9054. PubMed ID: 36670542 [TBL] [Abstract][Full Text] [Related]
2. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance. Módos O; Reis H; Niedworok C; Rübben H; Szendröi A; Szász MA; Tímár J; Baghy K; Kovalszky I; Golabek T; Chlosta P; Okon K; Peyronnet B; Mathieu R; Shariat SF; Hollósi P; Nyirády P; Szarvas T Oncotarget; 2016 Jun; 7(26):39293-39301. PubMed ID: 27283768 [TBL] [Abstract][Full Text] [Related]
3. Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data. Reis H; Krafft U; Niedworok C; Módos O; Herold T; Behrendt M; Al-Ahmadie H; Hadaschik B; Nyirady P; Szarvas T Dis Markers; 2018; 2018():7308168. PubMed ID: 29721106 [TBL] [Abstract][Full Text] [Related]
4. Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas. Reis H; van der Vos KE; Niedworok C; Herold T; Módos O; Szendrői A; Hager T; Ingenwerth M; Vis DJ; Behrendt MA; de Jong J; van der Heijden MS; Peyronnet B; Mathieu R; Wiesweg M; Ablat J; Okon K; Tolkach Y; Keresztes D; Nagy N; Bremmer F; Gaisa NT; Chlosta P; Kriegsmann J; Kovalszky I; Timar J; Kristiansen G; Radzun HJ; Knüchel R; Schuler M; Black PC; Rübben H; Hadaschik BA; Schmid KW; van Rhijn BWG; Nyirády P; Szarvas T Int J Cancer; 2018 Oct; 143(7):1764-1773. PubMed ID: 29672836 [TBL] [Abstract][Full Text] [Related]
5. Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer. Thiem S; Herold T; Krafft U; Bremmer F; Tolkach Y; Szász AM; Kriegsmann J; Gaisa NT; Niedworok C; Szarvas T; Reis H Pathol Int; 2017 Dec; 67(12):597-601. PubMed ID: 29047227 [TBL] [Abstract][Full Text] [Related]
6. Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study. Pires-Luis AS; Martinek P; Alaghehbandan R; Trpkov K; Comperat EM; Perez Montiel DM; Bulimbasic S; Lobo J; Henrique R; Vanecek T; Pivovarcikova K; Michalova K; Pitra T; Hora M; Marques A; Lopes JM; Rogala J; Mareckova J; Michal M; Hes O Adv Anat Pathol; 2020 Sep; 27(5):303-310. PubMed ID: 32520749 [TBL] [Abstract][Full Text] [Related]
7. Prevalence of APC and PTEN Alterations in Urachal Cancer. Nagy N; Reis H; Hadaschik B; Niedworok C; Módos O; Szendrői A; Bíró K; Hager T; Herold T; Ablat J; Black PC; Okon K; Tolkach Y; Csizmarik A; Oláh C; Keresztes D; Bremmer F; Gaisa NT; Kriegsmann J; Kovalszky I; Kiss A; Tímár J; Szász MA; Rink M; Fisch M; Nyirády P; Szarvas T Pathol Oncol Res; 2020 Oct; 26(4):2773-2781. PubMed ID: 32754865 [TBL] [Abstract][Full Text] [Related]
8. Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. Collazo-Lorduy A; Castillo-Martin M; Wang L; Patel V; Iyer G; Jordan E; Al-Ahmadie H; Leonard I; Oh WK; Zhu J; McBride RB; Cordon-Cardo C; Solit DB; Sfakianos JP; Galsky MD Eur Urol; 2016 Nov; 70(5):771-775. PubMed ID: 27178450 [TBL] [Abstract][Full Text] [Related]
9. Mutational Profile Using Next-Generation Sequencing May Aid in the Diagnosis and Treatment of Urachal Adenocarcinoma. Cornejo KM; Cosar EF; Paner GP; Yang P; Tomaszewicz K; Meng X; Mehta V; Sirintrapun SJ; Barkan GA; Hutchinson L Int J Surg Pathol; 2020 Feb; 28(1):51-59. PubMed ID: 31496327 [No Abstract] [Full Text] [Related]
10. Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract. Mirkovic J; McFarland M; Garcia E; Sholl LM; Lindeman N; MacConaill L; Dong F; Hirsch M; Nucci MR; Quick CM; Crum CP; McCluggage WG; Howitt BE Am J Surg Pathol; 2018 Feb; 42(2):227-233. PubMed ID: 28984674 [TBL] [Abstract][Full Text] [Related]
11. Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma. Mack PC; Klein MI; Ayers KL; Zhou X; Guin S; Fink M; Rossi M; Ai-Kateb H; O'Connell T; Hantash FM; Oh WK; Newman S; Schadt EE; Chen R; Hirsch FR Oncologist; 2022 Jun; 27(6):476-486. PubMed ID: 35298662 [TBL] [Abstract][Full Text] [Related]
13. Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas. Crumley SM; Pepper KL; Phan AT; Olsen RJ; Schwartz MR; Portier BP Arch Pathol Lab Med; 2016 Jun; 140(6):529-35. PubMed ID: 26536055 [TBL] [Abstract][Full Text] [Related]
14. Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma. Mäkelä R; Arjonen A; Härmä V; Rintanen N; Paasonen L; Paprotka T; Rönsch K; Kuopio T; Kononen J; Rantala JK BMC Cancer; 2020 Jun; 20(1):590. PubMed ID: 32576176 [TBL] [Abstract][Full Text] [Related]
15. Clinical, prognostic, and therapeutic aspects of urachal carcinoma-A comprehensive review with meta-analysis of 1,010 cases. Szarvas T; Módos O; Niedworok C; Reis H; Szendröi A; Szász MA; Nyirády P Urol Oncol; 2016 Sep; 34(9):388-98. PubMed ID: 27267737 [TBL] [Abstract][Full Text] [Related]
16. Deciphering Genetic Alterations of Taiwanese Patients with Pancreatic Adenocarcinoma through Targeted Sequencing. Huang CC; Liu CY; Huang CJ; Hsu YC; Lien HH; Wong JU; Tai FC; Ku WH; Hung CF; Lin JT; Huang CS; Chiang HS Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163506 [TBL] [Abstract][Full Text] [Related]
17. Analysis of Intestinal Metaplasia Without Dysplasia in the Urinary Bladder Reveal Only Rare Mutations Associated With Colorectal Adenocarcinoma. Amin A; Murati-Amador B; Lombardo KA; Jackson CL; Grada Z; Palsgrove DN; Matoso A Appl Immunohistochem Mol Morphol; 2020; 28(10):786-790. PubMed ID: 31876604 [TBL] [Abstract][Full Text] [Related]
18. Next-Generation Sequencing Reveals Potential Predictive Biomarkers and Targets of Therapy for Urothelial Carcinoma in Situ of the Urinary Bladder. Garczyk S; Ortiz-Brüchle N; Schneider U; Lurje I; Guricova K; Gaisa NT; Lorsy E; Lindemann-Docter K; Heidenreich A; Knüchel R Am J Pathol; 2020 Feb; 190(2):323-332. PubMed ID: 31734230 [TBL] [Abstract][Full Text] [Related]
19. Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma. Roy S; Pradhan D; Ernst WL; Mercurio S; Najjar Y; Parikh R; Parwani AV; Pai RK; Dhir R; Nikiforova MN Mod Pathol; 2017 Aug; 30(8):1133-1143. PubMed ID: 28548125 [TBL] [Abstract][Full Text] [Related]
20. Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection. Gleeson FC; Kerr SE; Kipp BR; Voss JS; Minot DM; Tu ZJ; Henry MR; Graham RP; Vasmatzis G; Cheville JC; Lazaridis KN; Levy MJ Oncotarget; 2016 Aug; 7(34):54526-54536. PubMed ID: 27203738 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]